APA (7th ed.) Citation

V, P., RN, G., RL, C., LP, C., BJ, M., TJ, H., . . . BM, S. (2025). Repurposing Food and Drug Administration-approved cancer therapies: Exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 35(12), 101938. https://doi.org/10.1016/j.ijgc.2025.101938

Chicago Style (17th ed.) Citation

V, Podder, Grisham RN, Coleman RL, Cobb LP, Monk BJ, Herzog TJ, Gershenson DM, and Slomovitz BM. "Repurposing Food and Drug Administration-approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-grade Serous Ovarian Cancer Treatment." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 35, no. 12 (2025): 101938. https://doi.org/10.1016/j.ijgc.2025.101938.

MLA (9th ed.) Citation

V, Podder, et al. "Repurposing Food and Drug Administration-approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-grade Serous Ovarian Cancer Treatment." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, vol. 35, no. 12, 2025, p. 101938, https://doi.org/10.1016/j.ijgc.2025.101938.